APRI Apricus Biosciences, Inc.

1.50
+0  (0%)
Previous Close 1.50
Open 1.58
Price To book 0.00
Market Cap 11.63M
Shares 7,733,000
Volume 199,922
Short Ratio 1.35
Av. Daily Volume 253,651

SEC filingsSee all SEC filings

  1. S-8 - Securities to be offered to employees in employee benefit plans 17505373
  2. 8-K - Current report 162069111
  3. 8-K - Current report 162026538
  4. 8-K - Current report 162011546
  5. 8-K - Current report 162006475

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

NDA resubmission planned for 3Q 2017.
Vitaros
Erectile dysfunction
Phase 2b planned - seeking partnership
RayVa
Secondary Raynaud’s Phenomenon

Latest News

  1. Latest Reports on Biocept and Apricus Biosciences as President Trump's Comments Put Pressure on Drug Manufacturers
  2. Apricus Biosciences Promotes Mary Naggs to Vice President, General Counsel
  3. Apricus Biosciences Promotes Mary Naggs to Vice President, General Counsel
  4. Apricus Biosciences Promotes Mary Naggs to Vice President, General Counsel
  5. Apricus Launches Vitaros in Lebanon for Erectile Dysfunction
  6. Apricus Biosciences Announces the Launch of Vitaros® for the Treatment of Erectile Dysfunction in Lebanon by Elis Pharmaceuticals
  7. Apricus Biosciences Announces the Launch of Vitaros® for the Treatment of Erectile Dysfunction in Lebanon by Elis Pharmaceuticals
  8. Apricus Biosciences Announces the Launch of Vitaros® for the Treatment of Erectile Dysfunction in Lebanon by Elis Pharmaceuticals
  9. APRICUS BIOSCIENCES, INC. Files SEC form 8-K, Change in Directors or Principal Officers
  10. ETFs with exposure to Apricus Biosciences, Inc. : December 13, 2016
  11. Zacks.com featured highlights: Baxter International, MAM Software Group, Advanced Energy Industries, Apricus Biosciences and Copart
  12. 5 Efficient Stocks to Buy for Superlative Returns
  13. Apricus Biosciences Receives Nasdaq Compliance Notice
  14. Apricus Biosciences Receives Nasdaq Compliance Notice
  15. Apricus Biosciences Receives Nasdaq Compliance Notice
  16. APRICUS BIOSCIENCES, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or S
  17. Apricus Biosciences to Present at the 9th Annual LD Micro Main Event
  18. Apricus Biosciences to Present at the 9th Annual LD Micro Main Event
  19. APRICUS BIOSCIENCES, INC. Files SEC form 8-K, Change in Directors or Principal Officers
  20. Apricus Biosciences Aims to Resubmit Vitaros NDA in 2017

SEC Filings

  1. S-8 - Securities to be offered to employees in employee benefit plans 17505373
  2. 8-K - Current report 162069111
  3. 8-K - Current report 162026538
  4. 8-K - Current report 162011546
  5. 8-K - Current report 162006475
  6. 10-Q - Quarterly report [Sections 13 or 15(d)] 161981601
  7. 8-K - Current report 161981426
  8. 8-K - Current report 161950517
  9. D - Notice of Exempt Offering of Securities 161934210
  10. SC 13G - Statement of acquisition of beneficial ownership by individuals 161926078